Laboratory-Based Evaluation of SD Bioline HIV/Syphilis Duo Rapid Test Kits in the Gambia, November 2019

Research Article

Austin Biomark Diagn. 2016; 4(1): 1026.

Laboratory-Based Evaluation of SD Bioline HIV/Syphilis Duo Rapid Test Kits in the Gambia, November 2019

Jarju ML*, Mendy A, Sanneh ML, Singhateh A, Kijera M, Saho N, Jah FO, Jallow K, Ceesay M, Jagne S, Baldeh I and Sanneh B*

National Public Health Laboratory, Ministry of Health, Bertil Harding Highway, Kotu Layout, Kotu, The Gambia

*Corresponding author: Modou Lamin Jarju, National Public Health Laboratory, Ministry of Health, Bertil Harding Highway, Kotu Layout, Kotu, The Gambia

Bakary Sanneh, National Public Health Laboratory, Ministry of Health, Bertil Harding Highway, Kotu Layout, Kotu, The Gambia

Received: August 31, 2021; Accepted: October 01, 2021; Published: October 08, 2021

Abstract

Background: HIV and syphilis are mainly diagnosed using separate rapid test kits for the HIV counseling and testing (HCT), Prevention of Mother-to-Child Transmission of HIV (PMTCT) and other clinical requests in healthcare facilities in The Gambia, as recommended in the HIV testing management guidelines. The goal of this study was to evaluate the performance of SD Bioline HIV/ Syphilis Duo as a single test kit used for the simultaneous detection of HIV & Syphilis antibodies in the laboratory setting.

Methods: We determined the sensitivity, specificity, positive and negative predictive values of SD Bioline HIV/Syphilis Duo kits in terms of HIV screening against the GenScreen Ultra HIV Ag-Ab ELISA (Lot 9D0126) using a total of 100 HIV negative and 150 HIV positive serum/plasma specimens that were stored at -20°C. Subtyping of the HIV positive specimens was previously performed using First Response HIV-1/2 test cards and Western Blot assays respectively. Moreover, the SD Bioline HIV/Syphilis Duo kit sensitivity, specificity, positive and negative predictive values in relation to Syphilis screening of 100 specimens was also determined against Treponema Pallidum Heamagglutination Assay (TPHA).

Results: In terms of HIV screening (n=250), the sensitivity, specificity, positive and negative predictive values of the SD Bioline HIV/Syphilis Duo Test Kits were 100%, 100%, 100%, and 100% respectively when compared with the GenScreen Ultra HIV Ag-Ab ELISA results in the laboratory setting. Sensitivity for Syphilis screening (n=100) was 95.65%, whilst specificity was 100% when compared with TPHA. Positive predictive value was 100%, whilst the negative predictive value was 98.86%.

Conclusions: These findings show that the SD Bioline HIV/Syphilis Duo kits have high sensitivity and specificity when used for the detection of HIV and Syphilis antibodies using human serum and/or plasma. Therefore, these kits could serve as a good alternative for the dual elimination of mother-to-child transmission (e-MTCT) HIV and Syphilis through a one-step timely diagnostic procedure, which is crucial in reducing the turnaround time of laboratory test results.

Keywords: HIV; Syphilis; SD Bioline; ELISA; TPHA; Gambia

Introduction

The number of people living with HIV (PLHIV) globally has reached 38·8 million in 2015. However, HIV/AIDS related mortality has declined from 1·8 million deaths in 2005, to 1.2 million deaths in 2015 [1]. Worldwide, approximately 930,000 maternal syphilis infections occurred in 2012. These infections caused 350,000 adverse pregnancy outcomes including 143,000 early fetal deaths and stillbirths, 62,000 neonatal deaths, 44,000 preterm or low weight births, and 102,000 infected infants [2]. In Comparison to the 2008 estimates, maternal syphilis decreased by 38% (from 1,488,394 cases in 2008 to 927,936 cases in 2012) and congenital syphilis decreased by 39% (from 576,784 to 350,915) [2]. Moreover, from 2008 to 2012, the proportion of women not screened for syphilis during pregnancy increased by 49% in the globe [3]. A review of interventions to screen and manage infections during pregnancy found that those focusing on syphilis demonstrated an 80% reduction in stillbirths, malaria (22% reduction), HIV (7% reduction) or bacterial vaginosis (12% reduction) [3]. It was also found that detection and treatment of syphilis before the third trimester (28 weeks) could revert the risk of adverse outcomes to background rates [3]. A rapid assessment of Sexually Transmissible Infections (STIs) in the Gambia found a prevalence of syphilis of 2.8% in1994 [4]. Another study in 2001 found that syphilis prevalence (7%) was higher among the 15-34 age group of the sexually active population [5]. Furthermore, a study in 2002 found a 3% prevalence of syphilis amongst antenatal women [6].

The first case of HIV/AIDS was discovered in The Gambia in 1986. Since then, the HIV epidemic in The Gambia has never gone beyond 5%. The Demographic and Health Survey (DHS) 2013 results shows that HIV prevalence among adults 15-49 years in The Gambia is 1.9% (DHS 2013) [7]. The National Sentinel survey (NSS) among antenatal women showed a declining trend of HIV prevalence from 2.8% in 2006 to 1.4% in 2016 [8,9]. However, the Integrated Bio-behavioral study (IBBS) conducted in 2011 have shown a high prevalence (15.9%) of HIV among female sex workers (FSW) [10]. Such vulnerable groups represent important groups for HIV prevention efforts not only because of their own increased HIV infection rates but because, through their clients that may act as reservoirs for the transmission of HIV, syphilis and other STI to the lower-risk groups in the population of the country [10].

HIV and syphilis are mainly diagnosed using separate rapid test kits for the HIV Counseling and Testing (HCT), Prevention of Mother to Child Transmission of HIV (PMTCT) and other clinical request in The Gambia as recommended in the HIV testing guidelines [11,12]. The rapid plasma reagent (RPR) is the rapid test kit for the diagnosis of syphilis even though a study in the country found that it is not very Sensitive (77%) and not recommended for syphilis diagnosis in poor environmental and resource limited countries [6]. Gliddon HD, et al. 2017 conducted a meta-analysis which included 18 laboratory and Field evaluation studies of diagnostic accuracy for HIV and syphilis and found that SD BIOLINE HIV/Syphilis Duo kit had the best diagnostic performance for screening of HIV and syphilis. The same review showed that dual screening for HIV and syphilis was more cost effective than single rapid tests for HIV and syphilis and prevented more adverse pregnancy outcomes [13]. Furthermore, the use of dual screening of HIV and syphilis as a point of care test was found to be highly acceptable to clients, who cited the quick turnaround time to get results, as well as less cheap services [13]. Studies have shown that SD BIOLINE HIV/Syphilis Duo Test kit is more accurate in the detection of HIV than syphilis [13]. However, most of them were laboratory-based with few field-based diagnostic performances done in resource limited settings [13]. This study intends to evaluate the performance of SD Bioline HIV/Syphilis Duo Test for the rapid testing of HIV and syphilis in the country in the laboratory environment.

Materials and Methods

Specimens

The specimens for this study were obtained from banked human serum/plasma harvested from whole blood specimens of patients/ clients who underwent HCT and PMTCT services at health facilities across the country. A total of 350 serum/plasma specimens (100 HIV negative, 50 HIV-1, 50 HIV-2, 50 HIV-1/2, and 100 specimens for Syphilis screening) were used in this evaluation. These specimens were initially screened for both HIV and Syphilis using separate diagnostic test kits. Storage of the specimens was done at -20°C at the Reference Serology Laboratory of the National Public Health Laboratories (NPHL), The Gambia. Based on the required sample size for this evaluation purpose, specimens were selected at random from the biobank of NPHL, taking into account the integrity of each specimen at the time of selection. Specimens not deemed fit for the purpose of this work were not selected.

Genscreen Ultra HIV Ag-Ab ELISA

All specimens selected for the evaluation of the SD Bioline HIV/Syphilis Duo test kits were first screened with Genscreen Ultra HIV Ag-Ab ELISA kit (Lot 9D0126) as the gold standard for HIV screening. A specimen distribution and identification plan (worksheet) was first generated followed by the preparation of diluted washing solution and conjugate working solution. Using a precision pipette, 25μL of conjugate 1 (R6) was added in wells that are part of the specimen distribution plan. This was subsequently followed by the addition of 75μL of HIV Ag positive control (R5) to well A1, 75μL of HIV Ab positive control (R4) to well B1, 75μL of HIV negative control (R3) to wells C1, D1 and E1, and 75μL of each specimen including an in-house control were added to their respective wells as per their positions on the specimen distribution and identification plan. This microplate was sealed with adhesive cover and placed in an incubator for 1 hour at 37°C ± 1°C. Following the 1-hour incubation, the adhesive cover was removed and the contents of the plate were washed away with an automated plate washer to get rid of unbound constituents. 100μL of conjugate 2 (R7a + R7b) was dispensed into each well. The microplate was again sealed and incubated for 30 minutes (±4 minutes) at room temperature (18-30°C). After this incubation procedure, the microplate was again washed as described above. A substrate solution was prepared and 80μL was dispensed in all the wells. The microplate was subsequently incubated for 30 minutes (±4 minutes) at room temperature (18-30°C) followed by the addition of 100μL of stopping solution (R10). The optical density of the microplate was read at 450nm using a plate reader. Cut-off values for the tests were determined and results interpreted accordingly. The presence or absence of detectable antigen or antibodies of HIV-1 and/ or HIV-2 was determined by comparing the absorbance measured for each specimen against the calculated cut-off value for the test.

SD Bioline HIV/Syphilis Duo test

The kits were equilibrated at room temperature and the test device removed from the foil pouch. The test devices (cassettes) were labelled with the corresponding patient identification and 10μL of plasma/serum specimen was added into the specimen well of each cassette followed by the addition of three drops of assay diluent to the same well. Test results were interpreted between 15-20 minutes.

Simply Treponema pallidum heamagglutination assay

Reagents and specimens were placed on the laboratory bench to reach room temperature (15-25°C). Each serum specimen as well as controls were pre-diluted at 1:20 with Diluent in column 1 (A1-H1) of a microtiter plate (U-shaped bottom). This was followed by the pipetting and dispensing of volumes of 25μL from the pre-dilution to columns 2 and 3 (A2-H2 & A3-H3), which are the test cells and control cells columns respectively. A volume of 75μL of test cells reagent containing chicken erythrocytes coated with Treponema pallidum antigen was added to the test cell column (column 2) and 75μL of control cells reagents was added to the control cells column (column 3). This procedure was subsequently repeated to cater for all the 100 specimens that were to be tested. The microplate was gently mixed to generate a homogenous mixture of the reaction components. A cover was placed on the microplate followed by room temperature incubation (15-25°C) for 60 minutes. The plate was protected from direct sunlight, and vibrations. Finally, the hemagglutination patterns of the cells was observed and test results were interpreted accordingly.

Data collection and analysis

Data was collected from HCT and PMTCT laboratory registers at various public health facilities in The Gambia. Statistical analysis was done by using two-by-two tables for calculating sensitivity, specificity, positive and negative predictive values.

Ethical issues

In order to ensure patient safety and confidentiality, no individual names or addresses were used to identify the specimens used in this study. Hence, specimens were identified using numbers and/or codes. All the specimens used were obtained from patients/clients who consented to be tested for HIV and Syphilis. These patients/ clients signed consent forms prior to their specimens being collected at public health facilities in the country. As per the country’s HIV and Syphilis testing and treatment guidelines/programme, all HIV and Syphilis positive specimens and 10% of negative specimens are subject to further testing at the National Public Health Laboratories, which is the Reference Centre for HIV and Syphilis testing. As a result, no ethical clearance was needed for this evaluation study.

Results

Genscreen ultra HIV Ag-Ab ELISA versus SD Bioline HIV/ Syphilis Duo

In a bid to establish the diagnostic accuracy of the SD Bioline HIV/Syphilis kit, a total of 100 specimens that were initially found to be HIV negative on the Genscreen Ultra ELISA also tested negative on the SD Bioline HIV/Syphilis Duo kit. Similarly, 150 specimens that tested positive on Genscreen Ultra HIV Ag-Ab ELISA were also positive/reactive for HIV antibodies using the SD Bioline HIV/ Syphilis Duo kits (Figure 1 and 2).